Eusol Biotech Co.,Ltd. (TPEX:6652)
Taiwan
· Delayed Price · Currency is TWD 6.56
+0.21 (3.31%)
Mar 10, 2026, 1:46 PM CST
Eusol Biotech Company Description
Eusol Biotech Co.,Ltd. focuses on research and development of new drugs for the treatment of nerve injuries.
The company’s pipeline includes ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) for spinal cord injury, and SM-1, a 3-in-1 combination sleeping aid.
It also offers small molecule drugs including EPS221, a selective serotonin reuptake inhibitor; EPS222, a calcium channel blocker for cardiovascular disease; EPS251, a drug for rheumatology/anti-inflammation; and EA2501, a drug for anticoagulation.
The company was founded in 1994 and is headquartered in Taipei, Taiwan.
Eusol Biotech Co.,Ltd.
| Country | Taiwan |
| Founded | 1994 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Wan-Ya Zhang |
Contact Details
Address: No. 367, Fuxing N. Rd Taipei, 105401 Taiwan | |
| Phone | 886 2 2718 5128 |
| Website | eusol-biotech.com |
Stock Details
| Ticker Symbol | 6652 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0006652001 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Wan-Ya Zhang | Manager |
| Bing Song Li | Accounting Supervisor |